Phosphopeptide Inhibitors Target TrkB-PLCγ1 Signaling for Epilepsy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for limbic epilepsy, particularly complex partial seizures, are ineffective due to resistance to anticonvulsant drugs and lack of prevention or cure, with TrkB-mediated activation of PLCγ1 contributing to epileptogenesis.
Innovation Solution
Administration of a therapeutically effective amount of an interfering molecule that disrupts TrkB-mediated activation of PLCγ1, such as a phosphopeptide or antibody, to inhibit the TrkB-PLCγ signaling pathway, thereby treating, preventing, or reducing the progression of neurological disorders like epilepsy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anticonvulsant drugs are used to treat limbic epilepsy, then treatment is provided for symptomatic relief, but the treatment is ineffective due to drug resistance and lacks prevention or cure capability
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (TrkB-PLCγ1 signaling pathway) that drives epileptogenesis, rather than using broad-spectrum anticonvulsant drugs. By isolating and interfering with this specific pathway using antisense oligonucleotides or small molecule inhibitors, the treatment achieves effectiveness where conventional drugs fail due to resistance.
Solution Approach 2:
The patent introduces interfering molecules (antisense oligonucleotides or small molecule inhibitors) as intermediaries that specifically block the TrkB-PLCγ1 signaling pathway. These intermediaries prevent BDNF from activating TrkB and subsequently activating PLCγ1, thereby interrupting the epileptogenic process without affecting other neural functions.
2Reliability
If BDNF activates TrkB receptor, then neuronal survival and plasticity are promoted, but TrkB-mediated activation of PLCγ1 promotes limbic epileptogenesis
Solution Approach 1:
The patent segments the TrkB signaling pathway into distinct branches: one leading to neuronal survival (via PI3K/Akt pathway) and another leading to epileptogenesis (via PLCγ1 pathway). By specifically targeting and blocking only the PLCγ1 branch while leaving the survival pathway intact, the treatment eliminates harmful effects while preserving beneficial functions.
Solution Approach 2:
The patent applies local quality by selectively interfering with the PLCγ1 signaling branch at a specific molecular level. The interfering molecules are designed to bind specifically to PLCγ1 or its activation site on TrkB, creating a localized block that affects only this specific signaling route while allowing other TrkB-mediated functions to proceed normally.
Data Source
AI summary
The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides, that when administered disrupt TrkB-mediated activation of PLCγ1 phosphorylation. The invention further provides method of treatment comprising administering inhibitors of TrkB-mediated activation of PLCγ1 phosphorylation alone or in combination with other pharmaceutical compositions to prevent or ameliorate nervous system disorders such as epilepsy, stroke, anxiety, migraine, and pain.